Photodynamic therapy for superficial bladder cancer under local anaesthetic.
AuthorsShackley, David C
O'Flynn, K J
Betts, C D
Moore, James V
Clarke, Noel W
AffiliationPaterson Institute for Cancer Research, Christie Hospital, Manchester, UK. M20 4BX
MetadataShow full item record
AbstractOBJECTIVES: To evaluate the use of local anaesthesia (LA) in 5-aminolaevulinic acid (ALA) photodynamic therapy (PDT) for superficial transitional cell carcinoma (TCC) of the bladder, and to provide further toxicity and tolerability data on this new method within the context of a phase 1 trial. PATIENTS AND METHODS: ALA PDT was administered to 19 patients with recurrent superficial TCC (stage Ta/carcinoma in situ, grades 1-3) using escalating doses of ALA (3-6%) and 633 nm laser light (25-50 J/cm2) under various LA (lignocaine) protocols. Pain was assessed using a linear analogue scale from 0 to 10. The endpoints of tolerability and toxicity were assessed for the different LA, light and ALA doses, with lignocaine levels. RESULTS: ALA PDT is painful and requires some form of anaesthesia. The discomfort was immediate, associated with bladder spasm, and was a function of the ALA concentration rather than the total light dose given. Simple passive diffusion (PD) of 2% lignocaine instilled for 40 min before PDT gave adequate anaesthesia with 3% ALA (n=8; median pain score 1, range 0-2). With 6% ALA the pain was dramatically increased using PD (n=6; median pain score 8, range 5-10) and therefore the more potent LA technique of electromotive drug administration (EMDA) of 2% lignocaine was used, with excellent results (n=3; median pain score 1, range 0-2). All patients had transient bladder irritability that typically lasted 9-12 days, with no subjective/objective change in long-term bladder function. No other toxicity was reported. Serum lignocaine levels were minimal. CONCLUSION: Bladder ALA PDT is both safe and feasible under LA. At a dose of 3% ALA, the procedure was well-tolerated using PD of lignocaine. At higher doses (6% ALA) more effective anaesthesia is required and this can be obtained satisfactorily with EMDA of lignocaine. With refinement, ALA PDT may be feasible as an outpatient treatment for superficial bladder TCC.
CitationPhotodynamic therapy for superficial bladder cancer under local anaesthetic. 2002, 89 (7):665-70 BJU Int.
- A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma.
- Authors: Skyrme RJ, French AJ, Datta SN, Allman R, Mason MD, Matthews PN
- Issue date: 2005 Jun
- Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study.
- Authors: Berger AP, Steiner H, Stenzl A, Akkad T, Bartsch G, Holtl L
- Issue date: 2003 Feb
- The effect of photodynamic therapy on rat urinary bladder with orthotopic urothelial carcinoma.
- Authors: Grönlund-Pakkanen S, Wahlfors J, Talja M, Kosma VM, Pakkanen TM, Ala-Opas M, Alhava E, Moore RB
- Issue date: 2003 Jul
- Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer.
- Authors: Marti A, Jichlinski P, Lange N, Ballini JP, Guillou L, Leisinger HJ, Kucera P
- Issue date: 2003 Aug
- Phase I trial of photodynamic therapy in the treatment of recurrent superficial transitional cell carcinoma of the bladder.
- Authors: Walther MM, Delaney TF, Smith PD, Friauf WS, Thomas GF, Shawker TH, Vargas MP, Choyke PL, Linehan WM, Abraham EH, Okunieff PG, Glatstein E
- Issue date: 1997 Aug